Patents by Inventor Christopher A. Klebanoff

Christopher A. Klebanoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS TARGETING RAS MUTATIONS AND USES THEREOF
    Publication number: 20240091361
    Abstract: The presently disclosed subject matter provides novel T cell receptors (TCRs) that target a mutated RAS protooncogene. The presently disclosed subject matter further provides cells comprising such TCRs, and methods of using such cells for treating cancers associated with RAS.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. KLEBANOFF, Smita S. CHANDRAN
  • NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF
    Publication number: 20230058774
    Abstract: The present disclosure provides novel dominant negative Fas polypeptides comprising a first modification in the cytoplasmic domain and a second modification in the N-terminal region of human Fas. The present disclosure also provides cells comprising such novel dominant negative Fas polypeptides and an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)). Also provided are uses of the cells for treatment, e.g., for treating tumors and pathogen infections.
    Type: Application
    Filed: July 6, 2022
    Publication date: February 23, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Christopher A. Klebanoff, Fei Yi
  • T CELL RECEPTORS TARGETING PIK3CA MUTATIONS AND USES THEREOF
    Publication number: 20220110976
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 14, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. Klebanoff, Smita S. Chandran
  • IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
    Publication number: 20210214415
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to a cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)) and a dominant negative Fas polypeptide. In certain embodiments, the cells are antigen-directed and exhibit enhanced cell persistence, and enhanced anti-target treatment efficacy.
    Type: Application
    Filed: March 26, 2021
    Publication date: July 15, 2021
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Christopher A. Klebanoff, Tori N. Yamamoto, Nicholas P. Restifo
  • T CELL RECEPTORS TARGETING PIK3CA MUTATIONS AND USES THEREOF
    Publication number: 20210060076
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher Klebanoff, Smita S. Chandran
  • METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS
    Publication number: 20210060075
    Abstract: The presently disclosed subject matter provides in vitro methods for identify TCRs that target specific antigens. The presently disclosed subject matter further provides TCRs identified by the methods and immunoresponsive cells comprising such TCRs.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. Klebanoff, Smita S. Chandran